BRIEF published on 11/20/2024 at 15:33, 19 hours 4 minutes ago Braidwell LP Crosses Thresholds at DBV Technologies Actions Investment Crossing Thresholds DBV Technologies Braidwell LP
BRIEF published on 11/06/2024 at 22:35, 14 days 12 hours ago DBV Technologies Facing Financial Uncertainties in Q3 2024 Financial Results Cash Flow Net Loss Q3 2024 DBV Technologies
PRESS RELEASE published on 11/06/2024 at 22:30, 14 days 12 hours ago DBV Technologies Reports Third Quarter 2024 Financial Results DBV Technologies reports Q3 2024 financial results, with $46.4 million cash balance. Approves quarterly financial statements. Faces challenges in securing future financing Financial Results Financing Clinical Trials Cash Balance DBV Technologies
BRIEF published on 10/31/2024 at 09:05, 21 days 1 hour ago Braidwell LP Crosses Thresholds in DBV Technologies Warrants Actions DBV Technologies Participation Threshold Braidwell LP
BRIEF published on 10/22/2024 at 22:50, 29 days 11 hours ago DBV's Viaskin Peanut Patch Secures Regulatory Progress in US and EU FDA Approval DBV Technologies Viaskin Peanut Regulatory Update EMA Guidance
PRESS RELEASE published on 10/22/2024 at 22:45, 29 days 11 hours ago DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV Technologies announces positive regulatory updates for Viaskin Peanut Patch in the United States and Europe, aiming for Accelerated Approval for toddlers 1-3 years old Accelerated Approval Regulatory Updates DBV Technologies Viaskin Peanut Patch Toddlers
BRIEF published on 10/18/2024 at 22:35, 1 month 2 days ago DBV Technologies to Engage in ACAAI 2024 Congress DBV Technologies Allergy Treatment Peanut Allergy Viaskin Peanut Patch ACAAI 2024
PRESS RELEASE published on 10/18/2024 at 22:30, 1 month 2 days ago DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies to participate in ACAAI 2024 Congress, presenting on optimal peanut allergy treatment and sponsoring FIT Bowl. Viaskin Peanut patch for food allergies highlighted DBV Technologies Food Allergies Viaskin Peanut Patch ACAAI 2024 Congress Peanut Allergy Treatment
BRIEF published on 10/14/2024 at 22:35, 1 month 6 days ago DBV Technologies Share Capital Status as of September 30, 2024 Share Capital Voting Rights DBV Technologies Euronext Exchanges Listed Shares
BRIEF published on 09/23/2024 at 22:35, 1 month 27 days ago DBV Technologies Completes Screening of Subjects for Phase 3 VITESSE Clinical Trial Clinical Trial Phase 3 DBV Technologies Viaskin Peanut Peanut Allergy
Published on 11/21/2024 at 10:03, 35 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 38 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 38 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 3 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 13 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:04, 33 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 35 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 37 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 38 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 36 minutes ago Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 3 hours 40 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 18 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 53 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 53 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
